Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
PerioChip
Overview
What is PerioChip?
PerioChip® (chlorhexidine gluconate) is a small, orange-brown, rectangular chip (rounded at one end) for insertion into periodontal pockets. Each PerioChip weighs approximately 6.9 mg and contains 2.5 mg of chlorhexidine gluconate in a biodegradable matrix of hydrolyzed gelatin (cross-linked with glutaraldehyde). PerioChip also contains glycerin and purified water.
Chlorhexidine gluconate is an antimicrobial agent. Chemically, it is designated as 1,1'-hexamethylenebis [5-(-chlorophenyl)biguanide] di-D-gluconate, and its molecular formula is CHClN.2CHO. The molecular weight is 897.8. The structural formula of chlorhexidine gluconate is:
What does PerioChip look like?
What are the available doses of PerioChip?
Sorry No records found.
What should I talk to my health care provider before I take PerioChip?
Sorry No records found
How should I use PerioChip?
PerioChip is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. PerioChip may be used as a part of a periodontal maintenance program, which includes good oral hygiene and scaling and root planing.
One PerioChip is inserted into a periodontal pocket with probing pocket depth (PD) 5 mm or greater. Up to 8 chips may be inserted in a single visit. Treatment is recommended to be administered once every three months in pockets with PD remaining 5 mm or greater.
The periodontal pocket should be isolated and the surrounding area dried prior to chip insertion. The PerioChip should be grasped using forceps (such that the rounded end points away from the forceps) and inserted into the periodontal pocket to its maximum depth. If necessary, the PerioChip can be further maneuvered into position using the tips of the forceps or a flat instrument. The PerioChip does not need to be removed since it biodegrades completely.
In the unlikely event of PerioChip dislodgement (in the two pivotal clinical trials, only 8 chips were reported lost), several actions are recommended, depending on the day of PerioChip loss. If dislodgement occurs 7 days or more after placement, the dentist should consider the subject to have received a full course of treatment. If dislodgement occurs within 48 hours after placement, a new PerioChip should be inserted. If dislodgement occurs more than 48 hours after placement, the dentist should not replace the PerioChip, but reevaluate the patient at 3 months and insert a new PerioChip if the pocket depth has not been reduced to less than 5 mm.
What interacts with PerioChip?
Sorry No Records found
What are the warnings of PerioChip?
Sorry No Records found
What are the precautions of PerioChip?
Sorry No Records found
What are the side effects of PerioChip?
Sorry No records found
What should I look out for while using PerioChip?
PerioChip should not be used in any patient who has a known sensitivity to chlorhexidine.
Anaphylaxis, as well as serious allergic reactions, have been reported during postmarketing use with dental products containing chlorhexidine.
What might happen if I take too much PerioChip?
Sorry No Records found
How should I store and handle PerioChip?
Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09 190733Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09 190733Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09 190733Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09 190733Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09 190733PerioChip (chlorhexidine gluconate) 2.5 mg is supplied as a small, orange-brown, rectangular chip (rounded at one end), in cartons of 20 chips (NDC52096-001-22). Each chip is individually packed in a separate compartment of an aluminum blister pack. Store at 20° - 25°C with excursions permitted to 15° - 30° C (59° - 86°F). Rx only. PerioChip (chlorhexidine gluconate) 2.5 mg is supplied as a small, orange-brown, rectangular chip (rounded at one end), in cartons of 20 chips (NDC52096-001-22). Each chip is individually packed in a separate compartment of an aluminum blister pack. Store at 20° - 25°C with excursions permitted to 15° - 30° C (59° - 86°F). Rx only. PerioChip (chlorhexidine gluconate) 2.5 mg is supplied as a small, orange-brown, rectangular chip (rounded at one end), in cartons of 20 chips (NDC52096-001-22). Each chip is individually packed in a separate compartment of an aluminum blister pack. Store at 20° - 25°C with excursions permitted to 15° - 30° C (59° - 86°F). Rx only.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Chlorhexidine gluconate is active against a broad spectrum of microbes. The chlorhexidine molecule, due to its positive charge, reacts with the microbial cell surface, destroys the integrity of the cell membrane, penetrates into the cell, precipitates the cytoplasm, and the cell dies. Studies with PerioChip showed reductions in the numbers of the putative periodontopathic organisms and after placement of the chip. No overgrowth of opportunistic organisms or other adverse changes in the oral microbial ecosystem were noted. The relationship of the microbial findings to clinical outcome has not been established.
Non-Clinical Toxicology
PerioChip should not be used in any patient who has a known sensitivity to chlorhexidine.Anaphylaxis, as well as serious allergic reactions, have been reported during postmarketing use with dental products containing chlorhexidine.
The use of PerioChip in an acutely abscessed periodontal pocket has not been studied and therefore is not recommended. Although rare, infectious events including abscesses and cellulitis, which have been reported after scaling and root planing alone, have also been reported with the adjunctive placement of the PerioChip post scaling and root planing. Management of patients with periodontal disease should include consideration of potentially contributing medical disorders, such as cancer, diabetes, and immunocompromised status.
The most frequently observed adverse events in the two pivotal clinical trials were toothache, upper respiratory tract infection, and headache. Toothache was the only adverse reaction that was significantly higher ( = 0.042) in the PerioChip group when compared to placebo. Most oral pain or sensitivity occurred within the first week of the initial chip placement following SRP procedures, was mild to moderate in nature, and spontaneously resolved within days. These reactions were observed less frequently with subsequent chip placement at 3 and 6 months.
Table 3
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).